| 毕亚菊,杨洁,梁志超.补肾柔肝方联合重组人干扰素治疗高危型人乳头瘤病毒持续感染 42例的临床疗效[J].安徽医药,2022,26(7):1453-1457. |
| 补肾柔肝方联合重组人干扰素治疗高危型人乳头瘤病毒持续感染 42例的临床疗效 |
| Clinical efficacy of Bushen Rougan decoction combined with recombinant human interferon in the treatment of 42 patients with high-risk human papillomavirus persistent infection |
| |
| DOI：10.3969/j.issn.1009-6469.2022.07.042 |
| 中文关键词: 乳头状瘤病毒感染 补肾柔肝方 重组人干扰素 C反应蛋白质 CD4淋巴细胞计数 人乳头瘤病毒 临床疗效 |
| 英文关键词: Papillomavirus infections Bushen Rougan decoction Recombinant human interferon C-reactive protein CD4 lymphocyte count Human papilloma virus Clinical efficacy |
| 基金项目:河北省中医药管理局资助项目( 2019446) |
|
| 摘要点击次数: 980 |
| 全文下载次数: 371 |
| 中文摘要: |
| 目的探讨补肾柔肝方联合重组人干扰素治疗高危型人乳头瘤病毒(HPV)持续感染的临床疗效及安全性。方法选取 2017年月至 2019年 12月石家庄市中医院收治的 84例高危型 HPV持续感染病人，按随机数字表法分为对照组和试验组各 42例。对照组给予重组人干扰素阴道上药，试验组在对照组基础上给予补肾柔肝方颗粒。比较治疗后高危型 HPV转阴率、临床疗效、不良反应、血清炎性因子 C反应蛋白( CRP)、白细胞介素 -6(IL-6)、降钙素原( PCT)及外周血 CD4+、CD8+T淋巴细胞的表达及 CD4+/CD8+比值的差异性。结果治疗后试验组总转阴率 83.34%(35/42)高于对照组总转阴率 61.9%(26/42)(P<0.001)；试验组总有效率 95.24%(40/42)高于对照组总有效率 76.19%(32/40)(P<0.05)；试验组总不良反应发生率为 4.76%(2/ 42)低于对照组总不良反应发生率 14.28%(6/42)(P>0.05)；治疗后两组病人外周血 CD8+T细胞百分率低于治疗前，外周血 CD4+细胞百分率、 CD4+/CD8+比值高于治疗前( P<0.001)且治疗后试验组外周血 CD8+T细胞百分率低于对照组，外周血 CD4+细胞百分率、 CD4+/CD8+比值高于对照组( P<0.001)；后两组病人的 CRP、IL-6、PCT水平低于治疗前( P<0.001)且治疗后试验组的 CRP、IL-6、PCT水平均低于对照组( P<0.001)。结论补肾柔肝方联合重组人干扰素治疗高危型 HPV持治疗，续感染， |
| 英文摘要: |
| Objective To explore the clinical efficacy and safety of Bushen Rougan decoction combined with recombinant human in-terferon in the treatment of high-risk HPV persistent infection.Method A selection of 84 patients with high-risk HPV persistent infec-tion who were admitted to Shijiazhuang Hospital of Traditional Chinese Medicine from January 2017 to December 2019 were selectedand assigned into the control group and the test group with 42 cases each according to a random number table. The control group wasgiven recombinant human interferon vaginal medicine, while the test group was given Bushen Rougan Fang granules on the basis of the control group. The high-risk HPV negative rate, clinical efficacy, adverse reactions, serum inflammatory factors C-reactive protein (CRP), interleukin-6 (IL-6), and calcitonin after treatment Procalcitonin (PCT) and the expression of CD4+ and CD8+ T lymphocytes inperipheral blood and the difference of CD4+/CD8+ ratio were compared.Results After treatment, the total negative conversion rate ofthe test group [83.34% (35/42)] was higher than that of the control group [61.9% (26/42)] (P<0.001); the total effective rate of the test group [95.24% (40/42)] was higher than that of the control group [76.19% (32/40)] (P<0.05); the total adverse reaction rate of the test group [4.76% (2/42)] was lower than that of the control group [14.28% (6/42)] ( P>0.05); after treatment, the percentage of CD8+T cellsin the peripheral blood of the two groups was lower than that before treatment, the percentage of peripheral blood CD4+ cells and the ra-tio of CD4+/CD8+ were higher than before treatment (P<0.001), and the percentage of CD8+ T cells in peripheral blood after treatmentof the test group was lower than that of the control group, and the percentage of peripheral blood CD4+ cells and the ratio of CD4+/CD8+ were higher than those of the control group (P<0.001); after treatment, the levels of CRP, IL-6 and PCT of the two groups were lower than before treatment (P<0.001), and the levels of CRP, IL-6 and PCT in the test group after treatment were lower than those in the control group (P<0.001).Conclusions The clinical effect of Bushen Rougan decoction combined with recombinant human interfer-on in the treatment of high-risk human papillomavirus HPV persistent infection is significant, the side effects are small, the safety ishigh, and it can improve the body's immunity and reduce the level of serum inflammatory factors. It is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
